The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25158455 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Laura S Pradel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Breast Neoplasms, Thioctic Acid, Histone Deacetylase Inhibitors, Drug Synergism. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Open-Access-Fonds of the Heinrich Heine University Düsseldorf, German Research Foundation.
Abstract (Originalsprache)
Anti-estrogenic therapy is established in the management of estrogen receptor (ER)-positive breast cancer. However, to overcome resistance and improve therapeutic outcome, novel strategies are needed such as targeting widely recognized aberrant epigenetics. The study aims to investigate the combination of the aromatase inhibitor exemestane and the histone deacetylase (HDAC) inhibitor and antioxidant α-lipoic acid in ER-positive breast cancer cells. First, the enantiomers and the racemic mixture of α-lipoic acid, and rac-dihydro-lipoic acid were investigated for HDAC inhibition. We found HDAC inhibitory activity in the 1–3-digit micromolar range with a preference for HDAC6. Rac-dihydro-lipoic acid is slightly more potent than rac-α-lipoic acid. The antiproliferative IC50 value of α-lipoic acid is in the 3-digit micromolar range. Notably, the combination of exemestane and α-lipoic acid resulted in synergistic behavior under various incubation times (24 h to 10 d) and readouts (MTT, live-cell fluorescence microscopy, caspase activation) analyzed by the Chou–Talalay method. α-lipoic acid increases mitochondrial fusion and the expression of apoptosis-related proteins p21, APAF-1, BIM, FOXO1, and decreases expression of anti-apoptotic proteins survivin, BCL-2, and c-myc. In conclusion, combining exemestane with α-lipoic acid is a promising novel treatment option for ER-positive breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
- Institute of Bio- and Geosciences (IBG-4: Bioinformatics), Forschungszentrum Jülich, 52425 Jülich, Germany.
ORCID-Profile: Laura S Pradel, Yu-Lin Ho, Holger Gohlke, Matthias U Kassack
Förderung
- Open-Access-Fonds of the Heinrich Heine University Düsseldorf
- German Research Foundation
Zitieren
APA
Pradel, L. S., Ho, Y. L., Gohlke, H., & Kassack, M. U. (2024). The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25158455
Vancouver
Pradel LS, Ho YL, Gohlke H, Kassack MU. The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25158455
BibTeX
@article{Pradel2024,
author = {Pradel, Laura S and Ho, Yu-Lin and Gohlke, Holger and Kassack, Matthias U},
title = {The Antioxidant and HDAC-Inhibitor α-Lipoic Acid Is Synergistic with Exemestane in Estrogen Receptor-Positive Breast Cancer Cells},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25158455}
}
EUVIMED